Key result
Fe(III) complexes of adriamycin and daunorubicin display antitumor activity against P 388 leukemia that compares with that of the free drug.
Iron(III) complexes of adriamycin and daunorubicin maintain antitumor activity comparable to the free drugs while potentially altering electron flow catalysis.
Answers are grounded in this paper and cite their sources.
May support preclinical development of Fe(III) anthracycline complexes; leaves open clinical translation from animal leukemia models.
Fe(III) complexes of two anthracyclines, adriamycin and daunorubicin, have been studied. Using potentiometric and spectroscopic measurements, we have shown that adriamycin and daunorubicin form two well-defined species with Fe(III), which can be formulated as respectively Fe(HAd)3 and Fe(HDr)3. In these formulas, HAd and HDr stand for adriamycin and daunorubicin in which the 1,4-dihydroxy-anthraquinone moiety is half-deprotonated. Both complexes are six-membered chelates. The stability constant is beta = (2.5 +/- 0.5) X 10(28) for both complexes. Interaction with DNA has been studied showing that, despite strong coordination to Fe(III), anthracyclines are able to intercalate between DNA bases pairs, releasing the metal. These complexes display antitumor activity against P 388 leukemia that compares with that of the free drug. Fe(HAd)3, unlike adriamycin, does not catalyze the flow of electrons from NADH to molecular oxygen through NADH dehydrogenase. Moreover, it is shown that the triferric adriamycin compound so called "quelamycin" is in fact a mixture of Fe(HAd)3 and polymeric ferric hydroxide.
No takes yet. Share an insight, caveat, or question.
Beraldo et al. (1985) studied P 388 leukemia. Fe(III) complexes of adriamycin and daunorubicin vs. free drug was evaluated on antitumor activity against P 388 leukemia. Fe(III) complexes of adriamycin and daunorubicin display antitumor activity against P 388 leukemia that compares with that of the free drug.
Synapse has enriched 10 related papers. Consider them for comparative context: